HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Burton, R. C. Articles by Warner, N. L. Search for Related Content PubMed Articles by Burton, R. C. Articles by Warner, N. L.

In Vitro Induction of Tumor-Specific Immunity

III. Lack of Requirement for H-2 Compatibility in Lysis of Tumor Targets by T Cells Activated in Vitro to Oncofetal and Plasmacytoma Antigens^{1 ,2}

From the Genetics Unit, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Abstract

Many recent studies have demonstrated that cytotoxic T lymphocytes (CL) activated to various antigens other than those of the H-2 complex, will lyse target cells only when H-2 compatibility exists between the CL and target cell. From these observations, it has been inferred that T lymphocytes might only be capable of responding to H-2 antigen or antigens that become associated with H-2 region gene products. Our results suggest that this is not the case, and that in some situations, cytotoxic T lymphocytes can specifically lyse target cells of different H-2 types. Two in vitro systems are described where primary induction of cytotoxic T lymphocytes to oncofetal and plasmacytoma antigens results in CL capable of lysing suitable targets bearing these antigens, of either syngeneic or allogeneic derivation. Thus it is proposed that although interaction antigens involving H-2 components may preferentially activate T lymphocytes, this does not imply a restriction on the recognition potential of T lymphocytes.

Footnotes

¹ This work was supported by United States Public Health Service Research Grant CA 15600 from the National Cancer Institute. The National Health and Medical Research Council, Canberra, is in part pursuant to Contract 1-CB-23889 from the National Cancer Institute and by the Wellcome Foundation, U. K.

² Publication No. 2211 of the Walter & Eliza Hall Institute.

³ National Health & Medical Research Council post-graduate research scholar.

⁴ Post-doctoral research fellow of the Division of Radiation Oncology, University of California, San Francisco.

⁵ Reprint requests to Dr. Noel L. Warner, Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131.